Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism